Teleflex Incorporated (NYSE: TFX) is a Healthcare company (Medical - Instruments & Supplies) with a market capitalization of $6.3B. The Maz Rating grades it against the other companies in its sector.
Teleflex Incorporated's current Maz Rating and its five factor grades are for members: log in to see them.
At $159.60, Teleflex Incorporated trades at 19.2x trailing earnings, 2.8x sales and 1.9x book value, with an EV/EBITDA of 23.7. Over the last twelve months it generated about $2.2B of revenue and $329M of net income. It runs a gross margin of 58.3%, an operating margin of 9.9% and a net margin of 13.6%. It shows return on equity of 9.7%, return on invested capital of 3.2% and a free cash flow yield of 6.1%. On the balance sheet: a debt-to-equity ratio of 0.48 and a current ratio of 2.01. Over the past 52 weeks the share price ranged from $100.18 to $161.00, with a beta of 0.83.
Teleflex Incorporated pays a dividend yielding 0.85%, with 19% of earnings paid out. Its Maz Dividend Score is 1.83 out of 5, ranked against the other dividend payers in its sector (Safety 2.63, Growth 1.63, Yield 2.70, Consistency 3.27).
29 Wall Street analyst ratings cover the stock: 16 Buy and 13 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Teleflex Incorporated is a global medical technology company dedicated to designing, developing, manufacturing, and distributing single-use medical devices. These products are crucial for diagnostic and therapeutic procedures, particularly within critical care and surgical environments worldwide. Its comprehensive product portfolio includes: Vascular Access Solutions: Featuring the "Arrow" brand, these include catheters, advanced catheter navigation and tip positioning systems, and intraosseous access systems. They are essential for administering intravenous therapies, monitoring blood pressure, and drawing blood samples, all achievable through a single access point. Interventional Cardiology & Radiology Products: This segment covers various coronary catheters, therapies for structural heart conditions, and devices for peripheral intervention and cardiac assist. Key users include interventional cardiologists, radiologists, and vascular surgeons. Specific offerings comprise Arrow, Guideline, and Trapliner catheters, the Manta Vascular Closure Device, and Arrow Oncontrol systems. Anesthesia and Surgical Products: The company provides anesthesia and pain management products, serving hospitals, emergency medical services, and military health organizations. Its surgical division offers metal and polymer ligation clips, fascial closure systems for laparoscopic procedures, percutaneous surgical systems, and a range of other surgical instruments. Interventional Urology & General Urology: Teleflex's interventional urology offerings prominently feature the UroLift System, an innovative treatment for lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH). Additionally, it supplies general urology products like catheters, urine collection devices, catheterization accessories, and tools for operative endourology, alongside providing bladder management services. Respiratory Care Products: This category includes oxygen and aerosol therapy devices, spirometry equipment, and ventilation management systems, applicable across diverse healthcare settings. Teleflex serves a broad customer base, encompassing hospitals, healthcare providers, medical device manufacturers, and the home care market. Established in 1943, the company maintains its headquarters in Wayne, Pennsylvania.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, Teleflex Incorporated (TFX) passes 4 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global, Dow Jones and FTSE, and fails MSCI.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 27.7% / 30% · (Cash+Inv) / Mkt Cap (36m) 7.38% / 30% · Interest income / Revenue 0.40% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 27.7% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 7.38% / 33% · Receivables / Mkt Cap (36m) 6.51% / 49% · Interest income / Revenue 0.40% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 27.7% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 7.38% / 33.33% · Receivables / Mkt Cap (24m) 6.51% / 33.33% · Interest income / Revenue 0.40% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 36.1% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 5.34% / 33.33% · Receivables / Avg Assets (4Q) 5.42% / 33.33% · Interest income / Revenue 0.40% / 5% | Fail |
| FTSE | Debt / Total Assets 25.5% / 33.33% · (Cash+ST Inv) / Total Assets 6.78% / 33.33% · (Cash+Recv) / Total Assets 12.8% / 33.33% · Interest income / Revenue 0.40% / 5% | Pass |
It depends on the standard you follow. As of September 2026, Teleflex Incorporated (TFX) passes 4 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global, Dow Jones and FTSE, and fails MSCI.
Yes. Teleflex Incorporated is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
About 0.40% of each dividend: Teleflex Incorporated's interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.